miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

(2015) Nicola Amodio et al.   Oncotarget

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction

(2012) Carsten Goessl et al.   Annals of the New York Academy of Sciences

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

(2012) M. T. Di Martino et al.   CLINICAL CANCER RESEARCH

MicroRNAs in the Pathobiology of Multiple Myeloma

(2012) Marta Lionetti et al.   CURRENT CANCER DRUG TARGETS

Molecular Targets for the Treatment of Multiple Myeloma

(2012) Marco Rossi et al.   CURRENT CANCER DRUG TARGETS

Editorial: [Hot Topic: New Approaches in the Treatment of Multiple Myeloma: From Target-based Agents to the New Era of microRNAs (Dedicated to the Memory of Prof. Salvatore Venuta)]

(2012) P. Tassone et al.   CURRENT CANCER DRUG TARGETS

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

(2012) P. Tagliaferri et al.   CURRENT CANCER DRUG TARGETS

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

(2012) P. Tassone et al.   CURRENT CANCER DRUG TARGETS

MicroRNA as a novel drug target for cancer therapy

(2012) Xiaoxia Liu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

New insights into osteoclastogenic signaling mechanisms

(2012) Tomoki Nakashima et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

(2012) N Amodio et al.   Cell Death & Disease

The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis

(2011) Tomoyuki Nakasa et al.   ARTHRITIS AND RHEUMATISM

Suppression of hepatic stellate cell activation by microRNA-29b

(2011) Yumiko Sekiya et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling

(2011) Maria T. Di Martino et al.   BRITISH JOURNAL OF HAEMATOLOGY

The skeleton: a multi-functional complex organ. The role of key signalling pathways in osteoclast differentiation and in bone resorption

(2011) David J Mellis et al.   JOURNAL OF ENDOCRINOLOGY

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

(2011) T Calimeri et al.   LEUKEMIA

Changes in microRNA expression in peripheral mononuclear cells according to the progression of osteoarthritis

(2011) Atsushi Okuhara et al.   Modern Rheumatology

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

(2011) Monica Marra et al.   Nanomedicine-Nanotechnology Biology and Medicine

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

(2011) Aline G. Costa et al.   Nature Reviews Rheumatology

Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review

(2011) Niall M.H. McLeod et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

MicroRNA biogenesis and regulation of bone remodeling

(2011) Kristina Kapinas et al.   ARTHRITIS RESEARCH & THERAPY

Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas

(2010) Nicola Amodio et al.   AMERICAN JOURNAL OF PATHOLOGY

miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop

(2010) Kristina Kapinas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MicroRNAs in Cancer

(2009) Ramiro Garzon et al.   Annual Review of Medicine

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

(2009) R. Garzon et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects

(2009) M. Marra et al.   CURRENT CANCER DRUG TARGETS

Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy

(2009) P. Tassone et al.   CURRENT CANCER DRUG TARGETS

miR-29 suppression of osteonectin in osteoblasts: Regulation during differentiation and by canonical Wnt signaling

(2009) Kristina Kapinas et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications

(2008) Kenji Ishitsuka et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

(2008) E. van Rooij et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA